Position Statements
AACU Support for HB 3421-Coverage for Biomarker Testing
AACU publicly supports HB 3421-Coverage for Biomarker Testing, which would ensure the coverage of biomarker testing for Oregonians, when medically appropriate, for diagnosis, treatment, management, or ongoing monitoring.
AACU Policy Stance on Low Dose Vaginal Estrogen (Outdated Black Box Warnings)
AACU Policy Stance Supporting the Use of Augmented Intelligence (AI) In Urology
AACU is fully committed to supporting the use of augmented intelligence (AI) to assist urologists in improving patient care.
AACU Strongly Supports the Medicare Patient Access and Practice Stabilization Act
AACU is working to ensure that urologists are compensated fairly.
Medicare to End Expanded Telehealth Coverage in April 2025: What You Need to Know Right Now
AACU wants our members to know about the recent telehealth changes in case you have not heard. We would like to emphasize that this is only for Medicare at this time, but other payers will likely follow suit.
AACU Support Legislation on Health Care Professions: Deceptive Terms or Letters: Artificial Intelligence
AACU Supports The Societies for Pediatric Urology and the American Urological Association’s Stance on DSD
AACU is a Proponent of 340B Reform
AACU is Against Prior Authorization Policies
AACU Strongly Supports Biomarker Testing
AACU Supports Payer Transparency
Genomic Testing in Prostate Cancer
Advances in the laboratory increasingly provide clinicians with patient-specific genomic information that contributes to individualized risk-stratification, treatment planning, and assessment of hereditary cancer risk (Endorsed by LUGPA)… Read More
AACU Policy Development Process
The AACU is dedicated to developing and advancing heath policy education as it affects urologic practice in order to preserve and promote the professional autonomy of its members and support the highest quality of care for patients.
To do so, the AACU develops evidence-based policy opinions and advocates for these with appropriate bodies, in particular with governments at all levels and private third-party payers. Policy documents are not intended to and should not be treated as legal, medical, or business advice.